In mammals, methionine metabolism occurs mainly in the liver via methionine adenosyltransferase-catalyzed conversion to S-adenosylmethionine. Of the two genes that encode methionine adenosyltransferase(MAT1A and MAT2A), MAT1A is mainly expressed in adult liver whereas MAT2A is expressed in all extrahepatic tissues. Mice lacking MAT1A have reduced hepatic S-adenosylmethionine content and hyperplasia and spontaneously develop nonalcoholic steatohepatitis. In this study, we examined whether chronic hepatic Sadenosylmethionine deficiency generates oxidative stress and predisposes to injury and malignant transformation. Differential gene expression in MAT1A knockout mice was analyzed following the criteria of the Gene Ontology Consortium. Susceptibility of MAT1A knockout mice to CCl 4 -induced hepatotoxicity and malignant transformation was determined in 3-and 18-month-old mice, respectively. Analysis of gene expression profiles revealed an abnormal expression of genes involved in the metabolism of lipids and carbohydrates in MAT1A knockout mice, a situation that is reminiscent of that found in diabetes, obesity, and other conditions associated with nonalcoholic steatohepatitis. This aberrant expression of metabolic genes in the knockout mice was associated with hyperglycemia, increased hepatic CYP2E1 and UCP2 expression and triglyceride levels, and reduced hepatic glutathione content. The knockout animals have increased lipid peroxidation and enhanced sensitivity to CCl 4 -induced liver damage, which was largely due to increased CYP2E1 expression because diallyl sulfide, an inhibitor of CYP2E1, prevented CCl 4 -induced liver injury. Hepatocellular carcinoma developed in more than half of the knockout mice by 18 months of age. Taken together, our findings define a critical role for S-adenosylmethionine in maintaining normal hepatic function and tumorigenesis of the liver.
M
ethionine is an essential amino acid metabolized mainly by the liver, where it is converted, by the enzyme methionine adenosyltransferase (MAT), into Sadenosylmethionine (AdoMet), the main biological methyl donor (1) . About 50% of methionine metabolism and up to 85% of all methylation reactions occur in the liver (2) . In mammals, two genes encode MATs: MAT1A and MAT2A. MAT1A is expressed mainly in the adult liver, and MAT2A is expressed in all tissues, including fetal liver, hepatocellular carcinoma (HCC), and, in small quantities, the adult liver (2) . One of the features of human liver cirrhosis is abnormal metabolism of methionine, a characteristic described 50 years ago (3) . Thus, the rate of blood methionine clearance after an oral load of this amino acid is markedly reduced in patients with liver cirrhosis. Failure to metabolize methionine in human cirrhosis is associated with hypermethylation of the liver MAT1A gene promoter as well as reduced MAT1A mRNA content and MAT activity (4, 5) .
Numerous studies have demonstrated that when rats or mice are fed a diet deficient in lipotropes (methionine, choline), the liver develops steatosis within a few days (6) . If the deficient diet continues, the liver develops nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, with some animals developing HCC (6) . Nutritional studies have also demonstrated that insufficient dietary methyl causes a decrease in AdoMet (7) .
To determine to what extent lipotrope deficiency may exert its pathogenic effect in the liver through a decreased availability of AdoMet, we have recently generated a MAT1A knockout (MATO) mouse. As expected, blood methionine levels increased and the hepatic AdoMet content decreased in knockouts (8) . The observation that 3-month-old MATO mice have hepatic hyperplasia and are more prone to develop steatosis in response to a choline-deficient diet and the finding that at 8 months, knockouts spontaneously develop NASH (8) strongly suggest that AdoMet deficiency may be a key component of the mechanism by which lipotrope deficiency causes these hepatic lesions. Furthermore, these results suggest that the deficiency in MAT activity observed in human liver cirrhosis may contribute to the pathogenesis and progression of the disease.
Because NASH that develops in mice fed a methionine-and choline-deficient diet is strongly associated with hepatic microsomal lipid peroxidation and induction of the microsomal enzyme cytochrome P4502E1 (CYP2E1), the main enzyme involved with that process (9, 10), we have tested the hypothesis that lipid peroxidation and CYP2E1 are also increased in MATO mice. Moreover, because lipotrope deficiency can result in HCC (6) and 3-month-old MATO mice have hepatic hyperplasia, an early event during the neoplastic process, we also tested the hypothesis that AdoMet deficiency in MATO mice increases the risk for HCC. Our findings define a critical role for AdoMet in maintaining normal hepatic function and in the pathogenesis of NASH and hepatic malignant transformation.
MATERIALS AND METHODS

Animal studies
Studies examining the role of CYP2E1 in CCl 4 -induced hepatotoxicity were performed using 3-month-old male wild-type (WT) mice and MATO mice (8) . Mice were fed ad libitum a standard diet (Harland Teklad irradiated mouse diet 7912, Madison, WI). Animals were treated humanely, and all procedures were in compliance with our institutions' guidelines for the use of laboratory animals. Acute liver injury was induced by the i.p. injection of a solution of CCl 4 (Sigma, St. Louis, MO) and sterile olive oil (Sigma) at a dose of 1 µL of CCl 4 /g animal weight (100 µL final volume per animal; controls received same volume of olive oil). Four WT and MATO animals were used in each condition. For CYP2E1 inhibition studies, two doses of diallyl sulfide (DAS) (Aldrich Chemical Co., Milwaukee, WI), an inhibitor of CYP2E1 (11) , were administered to mice 12 h apart (200 mg/4 mL of corn oil/kg, per os; controls received the same volume of corn oil), and CCl 4 was administered 2 h after the second dose. Twenty-four hours after CCl 4 administration, animals were sacrificed by cervical dislocation and livers were removed. Liver samples were either snap-frozen in liquid nitrogen or formalin-fixed and embedded in paraffin for histology. Long-term studies on the effect of MAT1A deletion were carried out in 18-monthold MATO mice fed a normal diet.
Liver histology
Sections from formalin-fixed liver tissue were stained with hematoxylin and eosin and examined by two pathologists unaware of the animals' identity and treatment. Liver tissue from three to four animals in each condition were examined and compared.
RNA isolation and Northern hybridization analysis
Total liver RNA was isolated by the guanidinium thiocyanate method. RNA concentration was determined spectrophotometrically before use, and the integrity was checked by electrophoresis with subsequent ethidium bromide staining. Electrophoresis of RNA and gel blotting were carried out as described previously (8) . A 0.732-kb CYP2E1 cDNA probe (nucleotides 266-997) was cloned by reverse transcriptase-polymerase chain reaction from mouse liver (12) . The probe for cystathionine β-synthase (CBS) was the generous gift of Dr. J. T. Brosnan (Memorial University, Newfoundland, Canada). The probes for uncoupling protein 2 (UCP2), glutamatecysteine ligase catalytic (GCLC), modifier (GCLM) subunits, and glutathione (GSH) synthetase have been described elsewhere (13) (14) (15) .
Northern hybridization analysis was performed on total RNA by using standard procedures as described previously (8) . All probes were labeled with [ 32 P]dCTP by using a random-primer kit (RediPrime DNA Labeling System, Amersham Pharmacia Biotech, Piscataway, NJ). To ensure equal loading of RNA samples, membranes were also hybridized with a 32 P-labeled 18S rRNA cDNA probe. Autoradiography and densitometry (Gel Documentation System, Scientific Technologies, Carlsbad, CA, and NIH Image 1.60 software program) were used to quantitate relative RNA. Results of Northern blot analysis were normalized to 18S rRNA.
Genechip analysis
We have carried out a detailed analysis of the results reported in Lu et al. (8) , in which liver gene expression in WT and MATO mice were compared using the Affymetrix murine U74A array. Genes with a expression fold change ≥2.0 were classified according to the biological process category or first subcategory in which they are involved following the criteria of the Gene Ontology Consortium (16) .
Analytical determinations
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using the kit provided by Sigma Diagnostics. Malondialdehyde (MDA) concentration in serum from WT and MATO mice under the different experimental conditions was determined essentially as described previously (17) . Liver microsomal CYP2E1-dependent hydroxylation of p-nitrophenol (Sigma) to p-nitrocatechol was used as standard assay for quantifying CYP2E1 activity as previously reported (18) . GSH content was measured in liver extracts by highperformance liquid chromatography (8) . Liver triglyceride (TGL) content was measured as described previously (19) .
Statistics
Two-tailed nonpaired Student's t test was used for comparisons between two groups. ANOVA followed by Fisher's test was used for comparison of more than two groups. Significance was defined by P < 0.05.
RESULTS
Using oligonucleotide microarrays, we analyzed gene expression profiles in livers from 3-month-old WT and MATO mice. Because small changes in expression may result in severe disease (20) , genes with an expression fold change ≥2.0 were selected. Genes up-regulated in knockout liver were classified according to the biological processes in which they participate (Table 1 ) and the same was done for genes down-regulated in knockout liver ( Table 2) . As shown in Figure 1 , most genes that were up-regulated in MATO mouse liver clustered into four biological processes: cell communication; those that control cell growth and/or maintenance; those that control cell death; and those that control development. Most genes that were downregulated in MATO mouse were involved in metabolism (Fig. 1) . Some of the genes identified in these clusters have been previously implicated with hepatocyte differentiation and proliferation. For example, α-fetoprotein and MAT2A, which are markers of fetal liver, as well as proliferating cell nuclear antigen, peroxisome proliferator activator receptor-γ, and early growth response-1, which are markers of hepatocyte proliferation, were up-regulated in MATO mice. Similarly, altered gene expression was observed in a variety of genes known to be involved in acute phase response and oxidative stress. For example, orosomucoid, metallothionein 1 and 2, myeloperoxidase, lipopolysaccharide-binding protein, and CD14-and Fas-antigen were found to be up-regulated, whereas mitochondrial ribosomal protein S12, CYP4A10, and CYP4A14 were found to be down-regulated in MATO mice.
In addition, the expression of numerous genes involved in lipid and carbohydrate metabolism was altered in MATO mice liver. For example, glucose-6-phosphate dehydrogenase, which provides the majority of the NADPH for fatty acid synthesis; 3-hydroxy-3-methylglutaryl-CoA reductase, a key step in cholesterol synthesis; and phospholipid transfer protein, which plays an important role in human plasma HDL metabolism, were up-regulated in knockout mice. Likewise, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, an important regulatory enzyme of glucose metabolism whose overexpression in mouse liver decreases gluconeogenesis; glycerol kinase, an important enzyme in TGL synthesis; and phosphoglycerate dehydrogenase, an enzyme that channels glycerol into the glycolytic pathway, were up-regulated in our microarray analysis of MATO mice.
Consistent with this abnormal expression of genes involved in lipid and carbohydrate metabolism, MATO mice had elevated hepatic TGL levels (26.4±4.2 mg/g wet liver in WT mice vs. 114.5±33.1 mg/g wet liver in MATO mice, P<0.05) and hyperglycemia (8.17±0.72 mmol/l glucose in WT mice vs.11.06±0.97 mmol/l in MATO mice, P<0.05), although the circulating levels of insulin were normal (0.99 ng/ml insulin in WT vs. 0.92 ng/mL in MATO mice). Because CYP2E1 is up-regulated in diabetes and obesity as well as by ethanol treatment (21), we tested the hypothesis that CYP2E1 was also increased in MATO mouse. We observed that liver CYP2E1 mRNA and activity were induced in 3-month-old MATO mice with respect to WT animals ( Figs. 2A and B) and that when knockout mice were treated with DAS, an effective inhibitor of CYP2E1 (11), hepatic CYP2E1 activity was decreased (Fig. 2B ).
To further demonstrate that CYP2E1 activity is indeed up-regulated in knockout mice, we determined the toxicity of CCl 4 , a hepatotoxic molecule that is biotransformed by CYP2E1. Histological analysis revealed that liver injury caused by CCl 4 was much more severe in MATO mice than in WT animals ( Fig. 3A) and that DAS administration prevented CCl 4 -induced liver injury in MATO mice (Fig. 3A) . As previously demonstrated (11), DAS treatment also ameliorated CCl 4 -induced liver injury in WT mice (Fig. 3A) . Liver injury was evaluated also by measuring blood AST and ALT levels. Baseline blood AST and ALT levels were similar in knockout and WT mice; however, the elevation of blood AST and ALT levels in response to CCl 4 was much higher in MATO mice than in WT animals ( Fig. 3B ). DAS pretreatment markedly reduced the elevation of AST and ALT levels caused by CCl 4 in knockout mice (Fig.  3B ). DAS administration also protected CCl 4 -induced AST and ALT elevation in WT mice (Fig.  3B ). In addition, the serum concentration of MDA, a measure of lipid peroxidation, was higher in MATO mice than in WT, and its increase in response to CCl 4 was also more pronounced in the knockout mice (Fig. 4A) . Again, DAS pretreatment reduced the generation of MDA induced by CCl 4 administration both in MATO mice and in WT animals ( Fig. 4A ).
We then determined the expression of UCP2, an anion carrier that uncouples the respiratory chain from oxidative phosphorylation and, hence, might enhance the vulnerability of hepatocytes to necrosis (22, 23). Although hepatocytes do not normally express uncoupling proteins, lipids up-regulate UCP2 expression in hepatocytes and obesity induces expression of UCP2 in hepatocytes and promotes liver ATP depletion (22, 23). We observed that the hepatic content of UCP2 mRNA was markedly induced in MATO mice with respect to WT animals ( Fig. 2A ).
CYP2E1 overexpression in human hepatocarcinoma HepG2 cells induces GSH synthesis by transcriptional activation of GCLC, the catalytic subunit of the rate-limiting enzyme in GSH synthesis (24, 25). It has been proposed that this may reflect an adaptive mechanism to remove CYP2E1-derived oxidants (24, 25). Accordingly, we tested the hypothesis that the expression of GSH synthetic enzymes may be increased in MATO mice. We observed that the hepatic mRNA levels of several key enzymes of the transsulfuration pathway involved in cysteine and GSH synthesis--CBS, GCL subunits, and GSH synthetase--were all increased in MATO mice compared with WT animals ( Fig. 2A ). Despite this increase in the expression of genes involved in GSH synthesis, the hepatic content of GSH, a critical factor for preserving normal cellular redox balance and protecting hepatocytes against oxidative stress (26), was reduced by ∼40% in knockout mice with respect to WT animals (Fig. 4B ). The addition of CCl 4 caused a reduction in the hepatic concentration of GSH in both types of animals, although the reduction was much more pronounced in the knockout mice (Fig. 4B) . Treatment with DAS induced an increase in hepatic GSH content both in WT and MATO mice ( Fig. 4B ) but had no effect on the depletion of hepatic GSH content triggered by CCl 4 in knockout mice and only a small protecting effect on the reduction of hepatic GSH in response to CCl 4 in WT mice (Fig. 4B ).
Finally, we tested the hypothesis that chronic AdoMet deficiency increases the risk for HCC. We observed that by 18 months of age, five (two male and three female) out of eight MATO mice (four male and four female) spontaneously developed HCC. The tumor is multifocal in two animals but unifocal in the other three. The tumor is composed of hepatocytes having round-tooval nuclei and prominent nucleoli, forming thickened trabecular cords lined by endothelial cells. Some of the tumor cells contain fat (Fig. 5) . Although the other three animals did not have HCC, their livers contained cystic and inflammatory changes (data not shown).
DISCUSSION
MAT1A encodes a catalytic subunit that organizes into dimers (MAT III) and tetramers (MAT I), and MAT2A encodes a catalytic subunit that associates to form MAT II (2) . Although the combination of MAT I/III provides the hepatocyte with a set of enzymes capable of efficiently metabolizing methionine without being inhibited by the cellular accumulation of AdoMet, MAT II is strongly inhibited by concentrations (micromole per liter) of AdoMet. Consequently, and although the disruption of MAT1A in MATO mouse leads to an increased expression of MAT2A, the capacity of the knockout mouse liver to metabolize methionine is markedly diminished, and this leads to hypermethioninemia and reduced hepatic AdoMet content (8) .
Analysis of the differential gene-expression profiles of knockout and WT mice suggests that MATO mice have abnormal lipid and carbohydrate metabolism. This was corroborated by the finding that MATO mice have elevated liver TGL levels and hyperglycemia. It is of interest that these alterations preceded any histological sign of steatosis or NASH in the knockout mice. CYP2E1 and UCP2 are known to be up-regulated by aberrant nutritional conditions such as diabetes and obesity (21-23). Thus, abnormal metabolism, rather than a direct effect of AdoMet, may be the trigger of the increased CYP2E1 and UCP2 expression in MATO mice. Consistent with this, hepatic CYP2E1 mRNA content was unchanged in 2-wk-old MATO mice, and exogenous AdoMet did not affect CYP2E1 expression in primary hepatocytes from 3-month-old MATO mice whereas, as previously demonstrated (27), it reduced MAT2A expression (data not shown).
Consistent with this increase in CYP2E1 activity, knockout mice were more prone to develop liver injury in response to CCl 4 . Analysis of the microarray data also revealed that the hepatic mRNA levels of CYP4A10 and CYP4A14 were reduced in MATO mice. These results agree with recent data indicating that the metabolic roles of CYP2E1 and CYP4A in lipid oxidation may be complementary and that the regulation of the expression of the individual enzymes is coordinated (10) . Thus, in CYP2E1-null mice, the hepatic expression of CYP4A genes is upregulated (10), and in obese diabetic ob/ob mice and fa/fa Zucker rats, in which CYP2E1 is down-regulated, CYP4A genes are up-regulated (28).
We also observed an increase in total lipid peroxides in serum and a marked decrease of hepatic GSH, proof that a deficiency in AdoMet generates hepatic oxidative stress in knockout mice. Hepatic GSH levels decreased in MATO mice, although the hepatic mRNA levels of several enzymes involved in cysteine and GSH synthesis were markedly increased. This agrees with our recent observation, using the intragastric infusion model of ethanol administration, that liver GSH levels declined even though GCL activity and GCL subunit mRNA levels increased (29). CYP2E1 overexpression in HepG2 cells also stimulated GSH synthesis by up-regulation of GCLC expression, although in this case, the GSH content of the hepatoma cells increased (24).
Although the up-regulation of antioxidant genes may reflect a general adaptive mechanism to dissipate oxidative stress generated by oxidant genes such as CYP2E1 and UCP2, the reduction in GSH content, despite the induction of its synthetic enzymes, may reflect other factors. These factors include the availability of cysteine via the transsulfuration pathway, which is important in determining the hepatic GSH content in the in vivo models but does not operate in hepatocarcinoma cells in culture. In the liver, AdoMet content regulates the fraction of homocysteine that is methylated to form methionine and the fraction that is converted into cysteine through the transsulfuration pathway (2). High hepatic AdoMet content activates the flow of homocysteine through the transsulfuration pathway, whereas low concentrations of AdoMet enhance methionine conservation (2) . Therefore, the reduced hepatic content of AdoMet in MATO mice will favor methionine conservation vs. the catabolism of homocysteine through the transsulfuration pathway and the synthesis of cysteine and GSH. Moreover, these results agree with earlier observations indicating that a reduction in hepatic AdoMet synthesis leads to a depletion of hepatic GSH content (30). Although AdoMet is an important source of cysteine in the normal liver, it cannot be converted to cysteine in HepG2 cells because of a block in the transsulfuration pathway (31). These important differences likely explain the seemingly discrepant GSH findings in the HepG2 cells overexpressing CYP2E1 compared with the MATO mice.
DAS treatment increased hepatic GSH content in both knockout and WT mice. Although this effect may be explained in part by its inhibitory effect on CYP2E1 activity, DAS has been shown to increase GSH-transferase activity and decrease GSH-peroxidase activity (32, 33), suggesting that this agent elicits other changes that may contribute to its GSH-sparing effect. Although DAS prevented CCl 4 -induced liver injury in both MATO and WT mice, this agent did not prevent CCl 4 -induced GSH depletion. These results suggest that liver injury induced by a single dose of CCl 4 is independent of the depletion of GSH induced by this agent. Moreover, the decline of GSH despite the inhibition of CYP2E1 by DAS suggests the existence of alternative pathways activated by CCl 4 that may reduce GSH, for example, cysteine availability.
Another important finding of this study was the observation that knockout mice spontaneously develop liver tumors. The induction in MATO mice of HCC strongly implies that MAT1A helps to prevent liver cancer through its capacity to maintain high AdoMet levels. This interpretation is consistent with our earlier work showing that, in hepatocarcinoma HuH-7 cells differing only in the type of MAT gene that is expressed, MAT2A expression associates with more rapid cell growth, whereas the opposite is observed for MAT1A (34). Cells expressing MAT2A had lower AdoMet levels than cells expressing MAT1A, and treatment of HuH-7 cells with AdoMet led to reduced cell growth (34). Moreover, AdoMet therapy has been shown to be effective in preventing the growth of rat HCC (35), and we have found that the addition of AdoMet to hepatocytes markedly inhibits HGF mitogenic activity (36, 37). Moreover, AdoMet accelerated the resynthesis of IκB and blunted the activation of NF-κB in cytokine-stimulated hepatocytes (38) .
Taken together, these results suggest a broad scenario in which hepatocytes are kept in a proliferative, immature state in response to a chronic deficiency in AdoMet. These immature hepatocytes have an impaired metabolism of lipids and carbohydrates, reminiscent of that found in diabetes and obesity as well as other conditions associated with NASH, which leads to the development of NASH and HCC. Additional studies are required to clarify the mechanism by which a chronic deficiency in AdoMet generates oxidative stress, particularly because impaired AdoMet synthesis is a common feature in human liver cirrhosis and this information may identify new targets for designing therapy of this disease. Ten-m4 (AB025413) Northern blot hybridization with 32 P-labeled-specific cDNA probes as described in Materials and Methods. The same membranes were rehybridized with a 32 P-labeled 18S rRNA cDNA probe to ensure equal loading. Representative Northern blots are shown. B) Hepatic CYP2E1 activity in MATO mice (knockout [KO] ) and WT animals untreated or treated with diallyl sulfide (DAS). Two doses of DAS were administered to mice 12 h apart, and animals were sacrificed 2 h after the second dose. CYP2E1 activity was determined as described in Materials and Methods. Results represent mean ± SD from four animals each.
A P < 0.001 for KO mice compared to WT mice.
B P < 0.001 for KO mice treated with DAS compared with untreated KO mice. 
